

Tetanus Toxoid (5.1B8): sc-80630

BACKGROUND

Clostridium tetani is a Gram-positive, motile, obligate anaerobe commonly found in soil and animal feces. *C. tetani* produces tetanospasmin, a powerful exotoxin that cleaves synaptobrevin II, an important protein component of synaptic vesicles, thus blocking the activity of inhibitory interneurons in the central nervous system. This leads to tetanus in humans, an acute, often fatal disease that is characterized by chronic muscle contraction, especially in the head and neck, which can eventually lead to respiratory failure. *C. tetani* poses a dangerous threat to humans, so prevention is important. Tetanus Toxoid is a substance that was purified from tetanospasmin in 1890, and it is currently used as a vaccine to produce active immunity against tetanus or to help boost the immune response to other vaccines.

REFERENCES

- Hendriksen, C. and Winsnes, R. 2003. Serological methods for potency testing of Tetanus Toxoid vaccines for human use. *Dev. Biol.* 11: 131-140.
- Katare, Y.K., Panda, A.K., Lalwani, K., Haque, I.U. and Ali, M.M. 2003. Potentiation of immune response from polymer-entrapped antigen: toward development of single dose Tetanus Toxoid vaccine. *Drug Deliv.* 10: 231-238.
- Tierney, R., Beignon, A.S., Rappuoli, R., Muller, S., Sesardic, D. and Partidos, C.D. 2003. Transcutaneous immunization with Tetanus Toxoid and mutants of *Escherichia coli* heat-labile enterotoxin as adjuvants elicits strong protective antibody responses. *J. Infect. Dis.* 188: 753-758.
- Seatovi, S., Ini-Kanada, A., Stojanovi, M., Zivkovi, I., Jankov, R.M. and Dimitrijevi, L. 2004. Development of sandwich enzyme-linked immunosorbent assay for determination of Tetanus Toxoid concentration. *J. Immunoassay Immunochem.* 25: 31-44.
- Bishop, N.C., Walker, G.J., Bowley, L.A., Evans, K.F., Molyneux, K., Wallace, F.A. and Smith, A.C. 2005. Lymphocyte responses to influenza and Tetanus Toxoid *in vitro* following intensive exercise and carbohydrate ingestion on consecutive days. *J. Appl. Physiol.* 99: 1327-1335.
- Danilova, E., Shiryayev, A., Kristoffersen, E.K. and Sjursen, H. 2005. Attenuated immune response to Tetanus Toxoid in young healthy men protected against tetanus. *Vaccine* 23: 4980-4983.
- Gupta, P.N., Mishra, V., Singh, P., Rawat, A., Dubey, P., Mahor, S. and Vyas, S.P. 2005. Tetanus Toxoid-loaded transfersomes for topical immunization. *J. Pharm. Pharmacol.* 57: 295-301.
- Wang, G., Molander, G., Koivuluhta, M., Alenius, H. and Lauerma, A. 2005. Decreased *in vitro* cellular response to Tetanus Toxoid and tuberculin in patients using topical corticosteroids. *Acta Derm. Venereol.* 85: 296-298.
- Mann, J.F., Scales, H.E., Shakir, E., Alexander, J., Carter, K.C., Mullen, A.B. and Ferro, V.A. 2006. Oral delivery of Tetanus Toxoid using vesicles containing bile salts (bilosomes) induces significant systemic and mucosal immunity. *Methods* 38: 90-95.

SOURCE

Tetanus Toxoid (5.1B8) is a mouse monoclonal antibody raised against full length formaldehyde-inactivated Tetanus Toxoid.

PRODUCT

Each vial contains 100 µg IgG₁ in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

Tetanus Toxoid (5.1B8) is recommended for detection of Tetanus Toxoid and toxin of *Clostridium tetani* origin by solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.